Los Angeles, California (PRWEB) July 30, 2012
Trader Investor Alert™ begins coverage and reporting on a small pharmaceutical company that fits their required client profile perfectly. Ampio Pharmaceuticals (AMPE) is developing drug and diagnostic products that are expected to have a high social impact by offering unrivaled treatments and diagnostics for today’s pandemic diseases of diabetes, arthritis, heart disease, cancer and sexual dysfunction. Additionally, management has demonstrated a very high level of integrity by never misrepresenting the clinical results and a very astute clinical plan that allows them to advance their drugs to pivotal trials in greatly reduced time and at a fraction of the cost incurred by most pharmaceutical companies.
The Ampio drugs in "fast-track" trials with the FDA are, Ampion™ for the treatment of osteoarthritis inflammation, Optina™ for the treatment of diabetic macular edema (DME), Zertane™ for the treatment of premature ejaculation (PE) and Zertane ED™ for both PE and ED (erectile dysfunction). Recently added to the clinical portfolio was NCE001 which has shown dramatic in-vivo effect on cell lines from breast cancer, renal cell cancer and glioblastoma multiforme.
Ampio is also expected to file a 510k submission with the FDA this year for approval of their ORP diagnostic Device (Oxidation Reduction Potential) that may prove to be a "breakthrough" method for hospitals to correctly evaluate the alarming number of patients presenting to the emergency department with chest pain by becoming a metric at or close to discharge that may reduce readmission associated costs both to hospitals and insurers.
Beyond momentum trading, news is one of the primary factors that influences traders and investors to buy or sell. Fortunately, the majority of financial news is accurate and can be relied upon most of the time. Unfortunately, there is a segment of the "news" that is misleading and responsible for a great deal of losses and lost opportunities by incorrectly inflating or deflating share prices. Either way, a misleading article, blog or tweet harms more people than the small number who stand to gain from it. It is this false or misleading news that gave birth and purpose to Trader Investor Alert™.
Capital markets like the New York Stock Exchange and Nasdaq have always played an important role in financing America’s necessary capital for growth, therefore, the share price and liquidity of a particular company’s shares in the marketplace have a great deal to do with how much capital a company can raise and how much it has to pay in dilution.
As it should be, small companies are typically focused on what they do best, i.e., developing their products or services. They are not experts in the public markets and the publicity and news surrounding their company. Companies like Trader Investor Alert™ help uncover and bring their true story to Wall Street and the rest of the world through careful research and through powerful social media. Trader Investor Alert™ interviews management face-to-face, one-on-one. Public records and filings are carefully researched and then reported with complete editorial control.
Trader Investor Alert™ may charge its clients for its services to stay in business, but resolutely maintains full editorial control of all publications. No company or client can censor or dictate what Trader Investor Alert™ publishes. There may even be certain negative disclosures reported about clients that may be frowned upon, but no matter what, only the true story will be printed.
Watch for reports and alerts on Ampio Pharmaceuticals.
About Trader Investor Alert™
Trader Investor Alert™ provides coverage of small companies with explosive stories that are frequently veiled by misleading information or that lack visibility. The companies covered must demonstrate high integrity and high social impact. Trader Investor Alert™ makes every attempt to report the news accurately and also covers significant developments that can easily be overlooked and cause extreme price and volume volatility. For more information: http://www.traderinvestoralert.com.